{"entity":{"id":"nct04959903","kind":"trial","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","aka":[],"tldr":"A phase 1/2 trial of Allogeneic T cell progenitors, cultured ex-vivo in advanced solid tumours, run by Smart Immune SAS, now recruiting.","summary":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT is a phase 1/2 interventional study registered as NCT04959903 by Smart Immune SAS, with 36 participants planned, started 2022-03-31 and due to reach its primary completion in 2025-08. Interventions recorded: Allogeneic T cell progenitors, cultured ex-vivo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04959903","url":"https://clinicaltrials.gov/study/NCT04959903"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04959903","phase":"1/2","setting":"A Phase I/II Study Evaluating the Safety and the Efficacy of SMART101 Injection to Accelerate Immune Reconstitution After T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Adult Patients With Hematological Malignancies","sponsor":"Smart Immune SAS","enrolled":36,"outcomes":[]},"route":"/trials/nct04959903/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}